F18-3F4AP
Phase 1Small molecule
F18-3F4AP is one of 8 small molecule programs targeting Neurodegeneration. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Neurodegeneration
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Approved
Dayvigo
EisaiPhase 2
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 2
F-18
BayerPhase 2
Namenda
AbbViePreclinical
Intropin
PfizerPreclinical
F-18-THK-5351
CChang Gung Memorial Hospital
Phase 2
F18-3F4AP
MMassachusetts General Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F18-3F4AP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMassachusetts General Hospital